Fewer than 1% of patients with type 1 diabetes achieve normal glycemic control (glycated hemoglobin [HbA1c] < 5.7%/ < 39 mmol/mol). Additionally, exogenous insulin administration often causes “iatrogenic hyperinsulinemia,” leading to whole-body insulin resistance and increased risk of cardiovascular complications. We present data on the clinical efficacy and safety of a long-term (10-year) ketogenic diet (≤50 g carbohydrates/day) therapy in a patient with type 1 diabetes. The use of a ketogenic diet resulted in successful glycemic control, assessed by HbA1c (5.5%; 36.6 mmol/mol), continuous glucose monitoring median glucose (98 mg/dL; 5.4 mmol/L), and glucose time-in-range of 70 to 180 mg/dL (90%) without acute glycemic complications. In conjunction, there was a** 43% decrease in daily insulin requirements**. Low-density lipoprotein cholesterol increased, whereas small-dense low-density lipoprotein was in the normal range (<90 nmol/L). No adverse effects were observed on thyroid function, kidney function, or bone mineral density. This case report demonstrates that a long-term ketogenic diet in a person with type 1 diabetes has considerable therapeutic benefits.

Full Text: https://doi.org/10.1210/jcemcr/luae102

  • jetOPMA
    link
    fedilink
    English
    arrow-up
    1
    ·
    12 days ago

    This lines up with Dr Bernstein’s work.

    Weaknesses

    • This is a case study of a single person

    Total insulin load decreased by 43% (from 0.67 IU/kg/day in 2013 to 0.38 IU/kg/day in 2023) during ketogenic diet therapy (Table 1). The decrease in insulin use was due to a decrease in bolus insulin and a marked shift in the percent of total insulin given as a basal dose (from 57% to 85%) and the percent given as a bolus dose (from 44% to 16%).

    The patient did not have any of the purported potential adverse effects of consuming a ketogenic diet